# Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

> **NCT06238648** · PHASE2 · RECRUITING · sponsor: **Academic and Community Cancer Research United** · enrollment: 120 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Primary Mediastinal Large B-Cell Lymphoma
- Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Epcoritamab
- **PROCEDURE:** Magnetic Resonance Imaging
- **OTHER:** Patient Observation
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT06238648
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-31
- **Primary completion:** 2029-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06238648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06238648, "Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy". Retrieved via MORVS 2026-10-07 from https://api.morvs.ai/clinical/NCT06238648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*